# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
Name and Address of Reporting Person * AISLING CAPITAL III LP				2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]								5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director  X 10% Owner				
888 SEVENTH AVE., 12TH FLOOR, (Middle)			_ ` ' '	3. Date of Earliest Transaction (Month/Day/Year) 07/06/2016							)	-	Officer (give	e title below)		er (specify belo	w)
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)							ear)		6. Individual or Joint/Group Filing(Check Applicable Line)  Form filed by One Reporting Person  X Form filed by More than One Reporting Person					
	ORK, NY 1											-2	X_ Form filed by	More than One	Reporting Perso	1	
(Cit	y)	(State)	(Zip)			7	Гable I - No	on-De	rivativ	e Secı	urities	s Acquire	ed, Disposed	of, or Bene	ficially Ow	ned	
1.Title of Security 2. Transaction (Instr. 3) Date (Month/Day/Year			2A. Deemed Execution Date, if			3. Transac Code (Instr. 8)	tion	(A) or	A) or Disposed of (D) nstr. 3, 4 and 5)		of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)			Ownership of	7. Nature of Indirect Beneficial	
	· ·			(Month/Day/Year)		Year)	Code	V	Amou		A) or (D)	Price	(Instr. 3 and 4)			Direct (D) Ov or Indirect (In (I) (Instr. 4)	Ownership (Instr. 4)
Common	Stock		07/06/2016				С		508,5	_	` /	(1) 5	508,565			D (2)	
Common	Stock		07/06/2016				P		400,0	00 A	١	\$ 12.5				D (2)	
Reminder:	Report on a	separate line for eac		Derivativ	ve Se	ecuriti		Pers cont form	ons what is a display	in thi ays a of, or	s for	m are no ently va	collection ot required lid OMB co	to respon	d unless th		1474 (9-02)
1. Title of Derivative Security (Instr. 3)  1. Title of 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. 5. N Transaction Deri Code Secu (Instr. 8) Acqu Disp		5. Nu Deriv Secur Acqu Dispo	umber of vative	6. Da and E	ate Exercisable Expiration Date nth/Day/Year)			rlying es and 4)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Owners Form of Derivati Security Direct ( or Indire	Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exerc	cisable	Expir Date	ation	Title	Amount or Number of Shares	r (Instr. 4)		(Instr. 4	)
Series B Preferred Stock	<u>(1)</u>	07/06/2016		С		]	1,907,122		(1)	(	1)	Commo Stock	INDX NON	\$ 0	0	D (2)	

## **Reporting Owners**

Powerting Owner Name / Address		Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
AISLING CAPITAL III LP 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X						
Aisling Capital Partners III LP 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X						
Aisling Capital Partners III LLC 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X						
ELMS STEVE C/O AISLING CAPITAL LLC 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X						
SCHIFF ANDREW N C/O AISLING CAPITAL LLC 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X						
Purcell Dennis J C/O AISLING CAPITAL LLC 888 SEVENTH AVE., 12TH FLOOR NEW YORK, NY 10106		X						

## **Signatures**

See Signatures on Exhibit 99.1	07/06/2016
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling (2) Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

#### FORM 4 JOINT FILER INFORMATION

Names of Joint Filers:

Aisling Capital III, LP Aisling Capital Partners III, LP Aisling Capital Partners III LLC Steve Elms Andrew N. Schiff, M.D. Dennis J. Purcell

Address of Joint Filers: c/o Aisling Capital Partners LLC 888 Seventh Avenue, 12<sup>th</sup> Floor New York, NY 10106

Designated Filer: Aisling Capital III, LP

Issuer and Ticker Symbol: Syros Pharmaceuticals, Inc. [SYRS]

Date of Event: July 6, 2016 Signatures of Joint Filers:

### AISLING CAPITAL III, LP

By: Aisling Capital Partners III, LP

General Partner

By: Aisling Capital Partners III LLC

General Partner

By: /s/ Lloyd Appel

Name: Lloyd Appel

Title: CFO

# AISLING CAPITAL PARTNERS III, LP

By: Aisling Capital Partners III LLC

General Partner

By: /s/ Lloyd Appel

Name: Lloyd Appel

Title: CFO

## AISLING CAPITAL PARTNERS III LLC

By: /s/ Lloyd Appel

Name: Lloyd Appel

Title: CFO

/s/ Steve Elms

Steve Elms

/s/ Andrew Schiff

Andrew Schiff

/s/ Dennis Purcell

Dennis Purcell